Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence
| Autor: | Brian Larsen Thorsted, Virginia Martín, Pedro Mezquita Raya, Hermione Price, Francisco Javier Ampudia Blasco, Barnaby Hunt, A Basse |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Insulin degludec
medicine.medical_specialty insulin Cost effectiveness Endocrinology Diabetes and Metabolism medicine.medical_treatment Cost-Benefit Analysis 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Diabetes Complications 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine cost Internal Medicine medicine Humans Hypoglycemic Agents real-world evidence cost-effectiveness Retrospective Studies business.industry Liraglutide Insulin Incidence (epidemiology) IDegLira Original Articles cost‐effectiveness real‐world evidence medicine.disease Insulin Long-Acting Drug Combinations Diabetes Mellitus Type 2 Clinical evidence Spain Original Article type 2 diabetes business Fixed ratio medicine.drug |
| Zdroj: | Diabetes, Obesity & Metabolism |
| ISSN: | 1463-1326 1462-8902 |
| Popis: | Aim To evaluate the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus comparator regimens for type 2 diabetes in Spain, based on real-world evidence. Materials and methods Clinical data were taken from the European Xultophy Treatment Retrospective Audit (EXTRA) real-world evidence study in which patients failing to meet glycaemic targets were switched to IDegLira. Baseline regimens (prior to IDegLira treatment) were categorized as: multiple daily insulin injections (MDI; 28%); glucagon-like peptide-1 (GLP-1) receptor agonists in combination with insulin (24%); basal insulin (19%); GLP-1 receptor agonists (10%); and non-injectable medications (19%). The IQVIA CORE Diabetes Model was used to project long-term outcomes for patients switching to IDegLira or continuing their baseline regimens (excluding non-injectable regimens). Costs were accounted from a Spanish National Health System perspective. Future costs and clinical benefits were discounted at 3% annually and sensitivity analyses were performed. Results IDegLira was projected to reduce the incidence of diabetes-related complications and improve quality-adjusted life expectancy versus all four comparators. IDegLira reduced direct medical costs versus GLP-1 receptor agonists in combination with insulin, and versus GLP-1 receptor agonist therapy, and was therefore considered dominant (cost saving while improving outcomes). IDegLira was found to be cost-effective versus MDI and basal insulin with incremental cost-effectiveness ratios of EUR 3013 per quality-adjusted life-year (QALY) gained and EUR 6890 per QALY gained, respectively. Conclusions Long-term projections based on real-world evidence indicated that IDegLira is likely to improve clinical outcomes and reduce costs or be cost-effective compared with other injectable regimens in people with type 2 diabetes in Spain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text